Novo Nordisk A/S’s shares fell by the most on record after patients using its experimental obesity shot CagriSema lost less weight than predicted in a study, throwing into question the drugmaker’s ...

helping Novo Nordisk to a record operating profit up 37% to DKK 75.8 billion. The performance is remarkable as both Ozempic and Wegovy are subject to rationing at the moment as demand outstrips ...

Novo Nordisk A/S (NYSE:NVO ... NVO is on track for its biggest daily and weekly percentage losses on record, as well as a fourth-straight loss. Shares now carry a 20% deficit for 2024, and ...

Thursday's gains put Novo Nordisk shares at a record high of more than $108. The stock gained more than 50% last year when booming demand for its diabetes and weight-loss drugs Ozempic and Wegovy ...

COPENHAGEN, Dec 5 (Reuters) - Danish drug maker Novo Nordisk (NOVOb.CO), opens new tab said on Thursday it will reduce the U.S. list prices of two insulin products by more than 70% from January of ...

(Bloomberg) -- Novo Nordisk A/S’s shares fell by the most on record after a failed attempt to leapfrog rival Eli Lilly & Co. in the red-hot market for obesity drugs. Novo’s experimental ...

Novo Nordisk’s shares fell by the most on record after patients using its experimental obesity shot CagriSema lost less weight than predicted in a study, throwing into question the drugmaker’s ...